NRX Selling General Administrative from 2010 to 2025
| NRXP Stock | USD 2.03 0.04 1.93% |
Selling General Administrative | First Reported 2018-03-31 | Previous Quarter 2.4 M | Current Value 2.6 M | Quarterly Volatility 9.2 M |
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 41.8 K, Interest Expense of 218.5 K or Selling General Administrative of 19.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
NRX | Selling General Administrative |
Latest NRX Pharmaceuticals' Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of NRX Pharmaceuticals over the last few years. It is NRX Pharmaceuticals' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRX Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
NRX Selling General Administrative Regression Statistics
| Arithmetic Mean | 10,197,852 | |
| Geometric Mean | 796,641 | |
| Coefficient Of Variation | 189.52 | |
| Mean Deviation | 12,486,677 | |
| Median | 134,480 | |
| Standard Deviation | 19,326,552 | |
| Sample Variance | 373.5T | |
| Range | 74.9M | |
| R-Value | 0.52 | |
| Mean Square Error | 290.3T | |
| R-Squared | 0.27 | |
| Significance | 0.04 | |
| Slope | 2,127,368 | |
| Total Sum of Squares | 5602.7T |
NRX Selling General Administrative History
About NRX Pharmaceuticals Financial Statements
NRX Pharmaceuticals shareholders use historical fundamental indicators, such as Selling General Administrative, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 13.5 M | 19.6 M |
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.